Fleury SA

Grupo Fleury reported Q1 2026 revenue of USD 2.22 billion (+10.1% YoY), exceeding expectations, while earnings per share of USD 0.35 narrowly missed the USD 0.354 estimate by 1.13%. Growth was driven mainly by the B2C segment; gross profit and EBITDA also rose by double digits. The stock fell 1.49% after hours; management emphasizes further investment in innovation and expansion while monitoring macroeconomic and regulatory risks. » Más en de.investing.com

Grupo Fleury posted revenue of R$2.4 billion in Q1 2026 (+10.1%), beating market expectations, while earnings per share of $0.35 slightly missed the $0.354 estimate. EBITDA rose to R$606.0 million (+10.7%) and net income to R$201.2 million (+12.2%), accompanied by a ROIC of 17% and a conservative leverage of 1.0x net debt/EBITDA. Management highlights successful diversification into an integrated health ecosystem, launched the Life‑Care offering, and expects further growth despite challenges in the B2B segment. » Más en de.investing.com

Grupo Fleury posted revenue growth of 12.2% in Q4 2025 to R$2.238bn and R$9.003bn for the full year (+8.2%). EBITDA rose 12.5% in the quarter to R$455.9m with a stable margin of 22.1%, and operating cash conversion was 99.9%; annual net income was R$612.8m. The company saw strong growth in the B2C segment and in New Links, maintains conservative leverage of 1.0x (net debt/EBITDA) and shows a high dividend yield of 10.65%. Despite results beating expectations, the stock fell after hours, reflecting profit-taking after last year’s strong run and uncertainty about sustainable growth rates. » Más en de.investing.com

Grupo Fleury reported Q4 2025 revenue of USD 2.06 billion and EPS of USD 0.138, both slightly above analysts' estimates. Despite strong results, the share price fell 3.38% in after-hours trading to USD 16.02. Operating cash flow and EBITDA margins remained robust; the outlook is stable with moderate EPS growth for 2026–2027. Risks include market saturation, economic pressure in Brazil, and currency fluctuations. » Más en de.investing.com

Grupo Fleury reported Q4 2025 EPS of $0.138 (forecast $0.1339) and revenue of $2.06 billion, both above expectations. Despite growth in B2C and B2B, a stable EBITDA margin (22.1%) and a 14.7% rise in net income, the stock fell 0.87% in after-hours trading to $16.03. The company reported margin pressure from high-priced drug applications, announced cost-optimization programs and gave an EPS forecast of $0.06 for Q1/Q2 2026 while continuing to focus on expanding its diagnostics portfolio. » Más en de.investing.com